Amedeo Smart

Free Medical Literature Service

 

Amedeo

Ischemic Heart Disease
  Free Subscription

Articles published in
N Engl J Med
    June 2026
  1. DILETTI R, Daemen J, Faurie B, Barbierato M, et al
    Intravascular Ultrasound-Guided or Angiography-Guided Complex High-Risk PCI.
    N Engl J Med. 2026;394:2200-2211.
    >> Share

    May 2026
  2. BIOLA H, Davis J, Khan SS, Lloyd-Jones D, et al
    Cardiovascular Risk Factors - Lifestyle Modifications.
    N Engl J Med. 2026;394:e44.
    >> Share

  3. BIOLA H, Khan SS, Lloyd-Jones D, Pagidipati NJ, et al
    Cardiovascular Risk Factors - Hypertension.
    N Engl J Med. 2026 May 20. doi: 10.1056/NEJMp2516850.
    >> Share

  4. SCHUNKERT H, Natarajan P, Samani NJ
    The Inherited Basis of Coronary Artery Disease. Reply.
    N Engl J Med. 2026;394:1967-1968.
    >> Share

  5. HINGORANI AD, Wald NJ
    The Inherited Basis of Coronary Artery Disease.
    N Engl J Med. 2026;394:1966-1967.
    >> Share

  6. LEE SJ, Yu HT, Kim JS
    Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents. Reply.
    N Engl J Med. 2026;394:1965-1966.
    >> Share

  7. FAUCHIER L, Guglieri M
    Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.
    N Engl J Med. 2026;394:1964-1965.
    >> Share

  8. CACOULIDIS C
    Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.
    N Engl J Med. 2026;394:1964.
    >> Share

    April 2026
  9. IBANEZ B, Jernberg T, Atar D
    Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction. Reply.
    N Engl J Med. 2026;394:1660-1661.
    >> Share

  10. OMEROVIC E
    Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction.
    N Engl J Med. 2026;394:1660.
    >> Share

  11. TURGEON R
    Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction.
    N Engl J Med. 2026;394:1659-1660.
    >> Share

  12. BOHULA EA, Giugliano RP, Sabatine MS
    Evolocumab for Primary Prevention of Cardiovascular Disease. Reply.
    N Engl J Med. 2026;394:1658-1659.
    >> Share

  13. BUDOFF MJ, Iskander B
    Evolocumab for Primary Prevention of Cardiovascular Disease.
    N Engl J Med. 2026;394:1658.
    >> Share

  14. GARCIA DE TENA J, Morales-Ortega A, Bernal-Bello D
    Evolocumab for Primary Prevention of Cardiovascular Disease.
    N Engl J Med. 2026;394:1658.
    >> Share

  15. KJELDSEN SE, Kreutz R, Mancia G
    Evolocumab for Primary Prevention of Cardiovascular Disease.
    N Engl J Med. 2026;394:1657-1658.
    >> Share

  16. PIRIS GONZALEZ M, Ortiz A
    Evolocumab for Primary Prevention of Cardiovascular Disease.
    N Engl J Med. 2026;394:1656-1657.
    >> Share

  17. LIN S, He Y, He L, Liu Y, et al
    Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease.
    N Engl J Med. 2026;394:1480-1490.
    >> Share

  18. SHARMA M, Dong Q, Hirano T, Kasner SE, et al
    Asundexian for Secondary Stroke Prevention.
    N Engl J Med. 2026;394:1467-1479.
    >> Share

  19. NICHOLLS SJ, Pavo I, D'Alessio D
    Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes. Reply.
    N Engl J Med. 2026;394:10.
    >> Share

  20. ANKER MS, Butler J, Anker SD
    Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.
    N Engl J Med. 2026;394:1551-1553.
    >> Share

  21. XU H, Cong X, Lin L
    Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.
    N Engl J Med. 2026;394:1551.
    >> Share

  22. VAN BRUGGEN F
    Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.
    N Engl J Med. 2026;394:1551.
    >> Share

  23. BECATTINI C, Agnelli G, Paciaroni M
    Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.
    N Engl J Med. 2026;394:1550-1551.
    >> Share

  24. CHUAN F, Gao Y, Zhou B
    Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.
    N Engl J Med. 2026;394:1550.
    >> Share

  25. SKEITH L, Bates SM
    Sex Hormone Influences on Venous Thrombotic and Cardiovascular Risk.
    N Engl J Med. 2026;394:1514-1528.
    >> Share

  26. CHOI KH, Kang D, Kim W, Doh JH, et al
    Discontinuation of Beta-Blocker Therapy after Myocardial Infarction.
    N Engl J Med. 2026;394:1302-1312.
    >> Share

    March 2026
  27. TESTA L, De la Torre Hernandez JM, De Maria GL, Jones DA, et al
    IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease.
    N Engl J Med. 2026 Mar 30. doi: 10.1056/NEJMoa2600440.
    >> Share

  28. WELT F
    Seeing the Left Main Coronary Artery Clearly - Is IVUS Always Necessary?
    N Engl J Med. 2026 Mar 30. doi: 10.1056/NEJMe2602959.
    >> Share

  29. DAEMEN J, van der Eijk JA, Barbierato M, Byrne RA, et al
    Angiography-Based Physiology to Guide Coronary Revascularization.
    N Engl J Med. 2026 Mar 29. doi: 10.1056/NEJMoa2601841.
    >> Share

  30. PERERA D, Ryan M, Ezad SM, Khan SQ, et al
    Left Ventricular Unloading in High-Risk Percutaneous Coronary Intervention.
    N Engl J Med. 2026 Mar 29. doi: 10.1056/NEJMoa2515704.
    >> Share

  31. LEE YJ, Lee SJ, Kim JW, Lee SH, et al
    Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease.
    N Engl J Med. 2026 Mar 28. doi: 10.1056/NEJMoa2600283.
    >> Share

  32. GUIMARAES PO, Franken M, Lemos PA
    Aspirin after PCI in Acute Coronary Syndromes. Reply.
    N Engl J Med. 2026;394:1036-1037.
    >> Share

  33. CHAN SCH
    Aspirin after PCI in Acute Coronary Syndromes.
    N Engl J Med. 2026;394:1036.
    >> Share

  34. LI M, Zhang G, Liu X
    Aspirin after PCI in Acute Coronary Syndromes.
    N Engl J Med. 2026;394:1035-1036.
    >> Share

  35. STRASSMEIR ML, Baumer U, Niessner A
    Aspirin after PCI in Acute Coronary Syndromes.
    N Engl J Med. 2026;394:1035.
    >> Share

  36. FEARON WF
    Assessing Nonculprit Coronary-Artery Lesions in STEMI.
    N Engl J Med. 2026;394:1021-1022.
    >> Share

    February 2026
  37. CEREDA A, Stracqualursi M, Lucreziotti S
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:821-822.
    >> Share

  38. MUNKHAUGEN J, Atar D, Prescott E
    Beta-Blockers after Myocardial Infarction. Reply.
    N Engl J Med. 2026;394:824-825.
    >> Share

  39. IBANEZ B, Latini R, Rossello X
    Beta-Blockers after Myocardial Infarction. Reply.
    N Engl J Med. 2026;394:823-824.
    >> Share

  40. ZIEMINSKI JJ, Bell MR
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:822-823.
    >> Share

  41. GAMARDELLA M, Ciconte G, Pappone C
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:822.
    >> Share

  42. LLOP D, Turu M, Llop C
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:821.
    >> Share

  43. CHI KY, Mangalesh S, Nanna MG
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:820-821.
    >> Share

  44. RAHHAL A, Al Hijji M, Arabi AR
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2026;394:820.
    >> Share

  45. LIP GYH, Kuzma L
    Thromboprophylaxis for Atrial Fibrillation in Patients with Drug-Eluting Stents.
    N Engl J Med. 2026;394:713-715.
    >> Share

  46. LUSCHER TF, Wenzl FA
    Beta-Blockers after Myocardial Infarction - Toward Personalized Management.
    N Engl J Med. 2026;394:599-602.
    >> Share

  47. SCHUNKERT H, Natarajan P, Samani NJ
    The Inherited Basis of Coronary Artery Disease.
    N Engl J Med. 2026;394:576-587.
    >> Share

    January 2026
  48. RYAN SJ, Jorstad OK, Skjelland M, Pesonen M, et al
    A Randomized Trial of Tenecteplase in Acute Central Retinal Artery Occlusion.
    N Engl J Med. 2026;394:442-450.
    >> Share

  49. THIELE H, Hassager C
    Cardiogenic Shock.
    N Engl J Med. 2026;394:62-77.
    >> Share

    December 2025
  50. NICHOLLS SJ, Pavo I, Bhatt DL, Buse JB, et al
    Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
    N Engl J Med. 2025;393:2409-2420.
    >> Share

    November 2025
  51. LEOPOLD JA
    Discontinuation of Aspirin in Acute Coronary Syndromes Treated with Coronary-Artery Stents.
    N Engl J Med. 2025;393:2164-2166.
    >> Share

  52. KRISTENSEN AMD, Rossello X, Atar D, Yndigegn T, et al
    Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction.
    N Engl J Med. 2025 Nov 9. doi: 10.1056/NEJMoa2512686.
    >> Share

  53. BOHULA EA, Marston NA, Bhatia AK, De Ferrari GM, et al
    Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
    N Engl J Med. 2025 Nov 8. doi: 10.1056/NEJMoa2514428.
    >> Share

  54. LEE SJ, Yu HT, Lee YJ, Lee SH, et al
    Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.
    N Engl J Med. 2025 Nov 8. doi: 10.1056/NEJMoa2512091.
    >> Share

  55. LOK CE, Farkouh M, Hemmelgarn BR, Moist LM, et al
    Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis.
    N Engl J Med. 2025 Nov 7. doi: 10.1056/NEJMoa2513032.
    >> Share

    October 2025
  56. NIJVELDT R, Maeng M, Beijnink CWH, Piek JJ, et al
    Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction.
    N Engl J Med. 2025 Oct 28. doi: 10.1056/NEJMoa2512918.
    >> Share

    September 2025
  57. MAGNUSSEN C, Lorenz T, Blankenberg S
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates. Reply.
    N Engl J Med. 2025;393:1247-1248.
    >> Share

  58. CORDERO L, Abasheva D, Ortiz A
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
    N Engl J Med. 2025;393:1246-1247.
    >> Share

  59. AKBARPOUR S, Azizpour Y, Larijani B
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
    N Engl J Med. 2025;393:1246.
    >> Share

  60. ZHENG X, Zhang J, Li Z
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
    N Engl J Med. 2025;393:1245-1246.
    >> Share

  61. COOPER KH
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
    N Engl J Med. 2025;393:1245.
    >> Share

  62. NICHOLLS SJ, Nelson AJ, Ray KK
    Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. Reply.
    N Engl J Med. 2025;393:928.
    >> Share

  63. GUO M, Liu Z
    Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.
    N Engl J Med. 2025;393:927-928.
    >> Share

  64. ZHANG D, Wu H, Gong S
    Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.
    N Engl J Med. 2025;393:927.
    >> Share

  65. MODARRESSI T
    Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.
    N Engl J Med. 2025;393:926-927.
    >> Share

  66. JEPPSSON A, James S, Moller CH, Malm CJ, et al
    Ticagrelor and Aspirin or Aspirin Alone after Coronary Surgery for Acute Coronary Syndrome.
    N Engl J Med. 2025 Sep 1. doi: 10.1056/NEJMoa2508026.
    >> Share

    August 2025
  67. TARANTINI G, Honton B, Paradies V, Lemesle G, et al
    Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction.
    N Engl J Med. 2025 Aug 31. doi: 10.1056/NEJMoa2508808.
    >> Share

  68. LEMESLE G, Didier R, Steg PG, Simon T, et al
    Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.
    N Engl J Med. 2025 Aug 31. doi: 10.1056/NEJMoa2507532.
    >> Share

  69. GUIMARAES PO, Franken M, Tavares CAM, Antunes MO, et al
    Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes.
    N Engl J Med. 2025 Aug 31. doi: 10.1056/NEJMoa2507980.
    >> Share

  70. MUNKHAUGEN J, Kristensen AMD, Halvorsen S, Holmager T, et al
    Beta-Blockers after Myocardial Infarction in Patients without Heart Failure.
    N Engl J Med. 2025 Aug 30. doi: 10.1056/NEJMoa2505985.
    >> Share

  71. IBANEZ B, Latini R, Rossello X, Dominguez-Rodriguez A, et al
    Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction.
    N Engl J Med. 2025 Aug 30. doi: 10.1056/NEJMoa2504735.
    >> Share

  72. TONET E, Raisi A, Zagnoni S, Chiaranda G, et al
    Multidomain Rehabilitation for Older Patients with Myocardial Infarction.
    N Engl J Med. 2025 Aug 29. doi: 10.1056/NEJMoa2502799.
    >> Share

  73. MCGUIRE DK, David JP, Inzucchi SE
    Oral Semaglutide and Cardiovascular Outcomes. Reply.
    N Engl J Med. 2025;393:725.
    >> Share

  74. DOS SANTOS MCF, de Lima NN, Lima JG
    Oral Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2025;393:724-725.
    >> Share

    July 2025
  75. MENSAH GA
    Estimates of Cardiovascular Risks and Benefits - When Knowing Is Not Enough.
    N Engl J Med. 2025;393:187-189.
    >> Share

    June 2025
  76. DAKIK HA
    Aspiration Thrombectomy for Coronary Stent Thrombosis.
    N Engl J Med. 2025;392:e52.
    >> Share

    May 2025
  77. JOLLY SS, d'Entremont MA, Mian R
    Colchicine and Spironolactone in Acute Myocardial Infarction. Reply.
    N Engl J Med. 2025;392:2075.
    >> Share

  78. JOLLY SS, d'Entremont MA, Lee SF
    Colchicine and Spironolactone in Acute Myocardial Infarction. Reply.
    N Engl J Med. 2025;392:2074-2075.
    >> Share

  79. GOLINO M, Van Tassell B, Abbate A
    Colchicine and Spironolactone in Acute Myocardial Infarction.
    N Engl J Med. 2025;392:2073-2074.
    >> Share

  80. KIDA Y
    Colchicine and Spironolactone in Acute Myocardial Infarction.
    N Engl J Med. 2025;392:2073.
    >> Share

  81. GU HQ, Jiang Y, Li H
    Colchicine and Spironolactone in Acute Myocardial Infarction.
    N Engl J Med. 2025;392:2072-2073.
    >> Share

  82. VAN TWIST DJL, Appelboom Y
    Colchicine and Spironolactone in Acute Myocardial Infarction.
    N Engl J Med. 2025;392:2072.
    >> Share

  83. STRIESSNIG J
    Colchicine and Spironolactone in Acute Myocardial Infarction.
    N Engl J Med. 2025;392:2071-2072.
    >> Share

  84. ZANNAD F
    Seeking Multiorgan Benefits with Cardiovascular-Kidney-Metabolic Drug Therapy.
    N Engl J Med. 2025;392:2061-2062.
    >> Share

  85. QIU Z, Li F, Sang H, Yuan G, et al
    Intravenous Tenecteplase before Thrombectomy in Stroke.
    N Engl J Med. 2025 May 21. doi: 10.1056/NEJMoa2503867.
    >> Share

  86. NICHOLLS SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, et al
    Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk.
    N Engl J Med. 2025 May 7. doi: 10.1056/NEJMoa2415820.
    >> Share

  87. RADER DJ
    Targeting Lipoprotein(a) - the Next Frontier in Cardiovascular Disease.
    N Engl J Med. 2025;392:1740-1742.
    >> Share

    March 2025
  88. MAGNUSSEN C, Alegre-Diaz J, Al-Nasser LA, Amouyel P, et al
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
    N Engl J Med. 2025 Mar 30. doi: 10.1056/NEJMoa2415879.
    >> Share

  89. MCGUIRE DK, Marx N, Mulvagh SL, Deanfield JE, et al
    Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.
    N Engl J Med. 2025 Mar 29. doi: 10.1056/NEJMoa2501006.
    >> Share

  90. KOTANIDIS CP, Maron DJ, Jernberg T
    Beta-Blocker Therapy after Acute Myocardial Infarction - To Block or Not to Block?
    N Engl J Med. 2025;392:1234-1236.
    >> Share

    February 2025
  91. RIDKER PM, Buring JE
    Biomarkers and 30-Year Cardiovascular Outcomes in Women. Reply.
    N Engl J Med. 2025;392:828.
    >> Share

  92. PEI C, Zhang W, Huang J
    Biomarkers and 30-Year Cardiovascular Outcomes in Women.
    N Engl J Med. 2025;392:828.
    >> Share

  93. GUI C, Huang Y
    Biomarkers and 30-Year Cardiovascular Outcomes in Women.
    N Engl J Med. 2025;392:827-828.
    >> Share

  94. CHO MS, Nam GB, Park DW
    Edoxaban for Atrial Fibrillation and Stable Coronary Artery Disease. Reply.
    N Engl J Med. 2025;392:826-827.
    >> Share

  95. SHIMAZU Y
    Edoxaban for Atrial Fibrillation and Stable Coronary Artery Disease.
    N Engl J Med. 2025;392:826.
    >> Share

  96. GREMMEL T
    Edoxaban for Atrial Fibrillation and Stable Coronary Artery Disease.
    N Engl J Med. 2025;392:826.
    >> Share

  97. KAWAI T, Williams WW, Elias N, Fishman JA, et al
    Xenotransplantation of a Porcine Kidney for End-Stage Kidney Disease.
    N Engl J Med. 2025 Feb 7. doi: 10.1056/NEJMoa2412747.
    >> Share

    January 2025
  98. SILVAIN J, Vicaut E, Montalescot G
    Beta-Blockers after Myocardial Infarction. Reply.
    N Engl J Med. 2025;392:100-101.
    >> Share

  99. CHI KY, Nanna MG
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2025;392:99.
    >> Share

  100. GASOWSKI J, Perera I, Piotrowicz K
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2025;392:99.
    >> Share

  101. VAN VOLLENHOVEN RF
    Beta-Blockers after Myocardial Infarction.
    N Engl J Med. 2025;392:99.
    >> Share

    December 2024
  102. PURI R
    The Art and Science of Managing Stable Coronary Artery Disease in Patients Undergoing TAVI.
    N Engl J Med. 2024;391:2267-2268.
    >> Share

  103. SALEH Y, Rios S
    Spontaneous Coronary-Artery Dissection.
    N Engl J Med. 2024;391:e54.
    >> Share

    November 2024
  104. FIORELLA D, Monteith SJ, Hanel R, Atchie B, et al
    Embolization of the Middle Meningeal Artery for Chronic Subdural Hematoma.
    N Engl J Med. 2024 Nov 20. doi: 10.1056/NEJMoa2409845.
    >> Share

  105. JOLLY SS, d'Entremont MA, Lee SF, Mian R, et al
    Colchicine in Acute Myocardial Infarction.
    N Engl J Med. 2024 Nov 17. doi: 10.1056/NEJMoa2405922.
    >> Share

  106. JOLLY SS, d'Entremont MA, Pitt B, Lee SF, et al
    Routine Spironolactone in Acute Myocardial Infarction.
    N Engl J Med. 2024 Nov 17. doi: 10.1056/NEJMoa2405923.
    >> Share

  107. RUBIN EJ, Leopold J, Morrissey S
    NEJM at AHA - Routine Spironolactone in Acute Myocardial Infarction.
    N Engl J Med. 2024 Nov 17. doi: 10.1056/NEJMe2414472.
    >> Share

  108. SAPP JL, Tang ASL, Parkash R, Stevenson WG, et al
    Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia.
    N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMoa2409501.
    >> Share

    October 2024
  109. HEATON K, Zern EK, Spahillari A, Barrett CD, et al
    Case 34-2024: A 69-Year-Old Man with Dyspnea after Old Myocardial Infarction.
    N Engl J Med. 2024;391:1633-1641.
    >> Share

  110. ALKAISSI H, Nazari MA, Hadrava Vanova K, Uher O, et al
    Rapid Cardiovascular Response to Belzutifan in HIF2A-Mediated Paraganglioma.
    N Engl J Med. 2024;391:1552-1555.
    >> Share

  111. JERNBERG T
    Routine Beta-Blockers in Secondary Prevention - Approaching Retirement?
    N Engl J Med. 2024;391:1356-1357.
    >> Share

    September 2024
  112. HABIB M, Aronson D
    Electrocardiographic Findings in Diffuse Subendocardial Ischemia.
    N Engl J Med. 2024;391:e19.
    >> Share

  113. RUBIN EJ, Leopold J, Morrissey S
    NEJM at ESC - Invasive versus Conservative Strategy for Older Patients with Myocardial Infarction.
    N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMe2410900.
    >> Share

  114. KUNADIAN V, Mossop H, Shields C, Bardgett M, et al
    Invasive Treatment Strategy for Older Patients with Myocardial Infarction.
    N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMoa2407791.
    >> Share

  115. RUBIN EJ, Leopold J, Morrissey S
    NEJM at ESC - Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease.
    N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMe2410903.
    >> Share

  116. LIP GYH
    Atrial Fibrillation and Stable Coronary Artery Disease.
    N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMe2409696.
    >> Share

  117. CHO MS, Kang DY, Ahn JM, Yun SC, et al
    Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease.
    N Engl J Med. 2024 Sep 1. doi: 10.1056/NEJMoa2407362.
    >> Share

    August 2024
  118. RUBIN EJ, Leopold J, Morrissey S
    NEJM at ESC - Inflammation, Cholesterol, Lipoprotein(a) and 30-Year Cardiovascular Outcomes in Women.
    N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMe2410895.
    >> Share

  119. BLUMENTHAL RS, Martin SS
    Prevention of Cardiovascular Disease - Don't Stop Thinking about Tomorrow.
    N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMe2409080.
    >> Share

  120. RIDKER PM, Moorthy MV, Cook NR, Rifai N, et al
    Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women.
    N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMoa2405182.
    >> Share

  121. LONBORG J, Jabbari R, Sabbah M, Veien KT, et al
    PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation.
    N Engl J Med. 2024 Aug 31. doi: 10.1056/NEJMoa2401513.
    >> Share

  122. SILVAIN J, Cayla G, Ferrari E, Range G, et al
    Beta-Blocker Interruption or Continuation after Myocardial Infarction.
    N Engl J Med. 2024 Aug 30. doi: 10.1056/NEJMoa2404204.
    >> Share

  123. RUBIN EJ, Leopold J, Morrissey S
    NEJM at ESC - Beta Blocker Interruption or Continuation with Prior Myocardial Infarction.
    N Engl J Med. 2024 Aug 30. doi: 10.1056/NEJMe2410891.
    >> Share

  124. MAHENDIRAN T, Collet C, De Bruyne B
    More on Coronary-Artery Autoregulation with Increasing Stenosis. Reply.
    N Engl J Med. 2024;391:671.
    >> Share

  125. YANG X, Wu M, Zhang G
    More on Coronary-Artery Autoregulation with Increasing Stenosis.
    N Engl J Med. 2024;391:670-671.
    >> Share

    July 2024
  126. BOHM F, James S
    FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction. Reply.
    N Engl J Med. 2024;391:288.
    >> Share

  127. LI P
    FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction.
    N Engl J Med. 2024;391:287-288.
    >> Share

  128. YNDIGEGN T, Hofmann R, Jernberg T
    Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. Reply.
    N Engl J Med. 2024;391:95.
    >> Share

  129. KOMAMURA K, Kobayashi K, Iwase M
    Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
    N Engl J Med. 2024;391:94-95.
    >> Share

  130. CLELAND JGF, McMurray JJV, Freemantle N
    Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
    N Engl J Med. 2024;391:94.
    >> Share

    June 2024
  131. MOLLER JE, Hassager C
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock. Reply.
    N Engl J Med. 2024;390:2328-2330.
    >> Share

  132. VON LEWINSKI D, Herold L, Toth GG
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2328.
    >> Share

  133. BALDETTI L, Pieri M, Scandroglio AM
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2328.
    >> Share

  134. ELKARYONI A, Hyder O, Saad M
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2327.
    >> Share

  135. FROM AM
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2327.
    >> Share

  136. MALLIDI J, Lotfi A
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2326-2327.
    >> Share

  137. THIELE H, Desch S, Zeymer U
    Microaxial Flow Pump in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:2325-2326.
    >> Share

  138. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
    Prevention of Cardiovascular Disease in Type 1 Diabetes. Reply.
    N Engl J Med. 2024;390:2227.
    >> Share

  139. MAAHS DM, Svensson J
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:2226-2227.
    >> Share

  140. WENSTEDT EFE, Vogt L
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:2226.
    >> Share

  141. LI S, Gu HQ, Li H, Wang X, et al
    Reteplase versus Alteplase for Acute Ischemic Stroke.
    N Engl J Med. 2024 Jun 14. doi: 10.1056/NEJMoa2400314.
    >> Share

  142. XIONG Y, Campbell BCV, Schwamm LH, Meng X, et al
    Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy.
    N Engl J Med. 2024 Jun 14. doi: 10.1056/NEJMoa2402980.
    >> Share

  143. MAHENDIRAN T, Collet C, De Bruyne B
    Coronary-Artery Autoregulation with Increasing Stenosis.
    N Engl J Med. 2024;390:2030-2032.
    >> Share

    May 2024
  144. KING G, Hamilton GW
    Left Ventricular Thrombus after Anterior Myocardial Infarction.
    N Engl J Med. 2024;390:e50.
    >> Share

  145. NATARAJAN P
    Exceptional Genetics, Generalizable Therapeutics, and Coronary Artery Disease.
    N Engl J Med. 2024 May 29. doi: 10.1056/NEJMe2405647.
    >> Share

  146. ALBERS GW, Purdon B, Campbell BCV
    Tenecteplase for Stroke at 4.5 to 24 Hours. Reply.
    N Engl J Med. 2024;390:1729.
    >> Share

  147. GOYAL M, Bosshart SL, Ospel JM
    Tenecteplase for Stroke at 4.5 to 24 Hours.
    N Engl J Med. 2024;390:1729.
    >> Share

  148. GRINSPOON SK, Ribaudo HJ, Douglas PS
    Trial Update of Pitavastatin to Prevent Cardiovascular Events in HIV Infection.
    N Engl J Med. 2024;390:1626-1628.
    >> Share

    April 2024
  149. STEG PG
    Routine Beta-Blockers in Secondary Prevention - On Injured Reserve.
    N Engl J Med. 2024;390:1434-1436.
    >> Share

  150. RAO SV
    Mechanical Circulatory Support in Cardiogenic Shock - Persistence and Progress.
    N Engl J Med. 2024;390:1436-1438.
    >> Share

  151. MOLLER JE, Engstrom T, Jensen LO, Eiskjaer H, et al
    Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock.
    N Engl J Med. 2024;390:1382-1393.
    >> Share

  152. BOHM F, Mogensen B, Engstrom T, Stankovic G, et al
    FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction.
    N Engl J Med. 2024 Apr 8. doi: 10.1056/NEJMoa2314149.
    >> Share

  153. KUNADIAN V
    Role of Physiology in the Management of Nonculprit Lesions in Acute Coronary Syndrome.
    N Engl J Med. 2024 Apr 8. doi: 10.1056/NEJMe2403527.
    >> Share

  154. YNDIGEGN T, Lindahl B, Mars K, Alfredsson J, et al
    Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
    N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2401479.
    >> Share

  155. BERGMARK BA, Marston NA, Prohaska TA, Alexander VJ, et al
    Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
    N Engl J Med. 2024 Apr 7. doi: 10.1056/NEJMoa2402309.
    >> Share

  156. GIBSON CM, Duffy D, Korjian S, Bahit MC, et al
    Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2400969.
    >> Share

  157. ROULEAU J
    Decreasing the Risk of Heart Failure in a Changing Post-Myocardial Infarction Environment.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMe2402719.
    >> Share

  158. BUTLER J, Jones WS, Udell JA, Anker SD, et al
    Empagliflozin after Acute Myocardial Infarction.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2314051.
    >> Share

  159. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:1207-1217.
    >> Share

    March 2024
  160. WHITE HD
    A Placebo-Controlled Trial of PCI for Stable Angina. Reply.
    N Engl J Med. 2024;390:10.
    >> Share

  161. AL-LAMEE RK, Rajkumar CA
    A Placebo-Controlled Trial of PCI for Stable Angina. Reply.
    N Engl J Med. 2024;390:1151-1152.
    >> Share

  162. DURANTE A, Baiardo Redaelli M
    A Placebo-Controlled Trial of PCI for Stable Angina.
    N Engl J Med. 2024;390:1150-1151.
    >> Share

  163. SHERROD CF 4TH, O'Keefe EL, Ikemura N
    A Placebo-Controlled Trial of PCI for Stable Angina.
    N Engl J Med. 2024;390:1150.
    >> Share

  164. BESTERMANN WH JR
    A Placebo-Controlled Trial of PCI for Stable Angina.
    N Engl J Med. 2024;390:1149-1150.
    >> Share

  165. ROSWELL RO, Wong MP, Stefanescu Schmidt AC, Petranovic M, et al
    Case 8-2024: A 55-Year-Old Man with Cardiac Arrest, Cardiogenic Shock, and Hypoxemia.
    N Engl J Med. 2024;390:1030-1043.
    >> Share

  166. CARSON JL, Brooks MM, Hebert PC
    Transfusion Strategy in Myocardial Infarction and Anemia. Reply.
    N Engl J Med. 2024;390:961-962.
    >> Share

  167. KHAN MS, Spertus JA, Chan PS
    Transfusion Strategy in Myocardial Infarction and Anemia.
    N Engl J Med. 2024;390:960-961.
    >> Share

  168. CHAPALAIN X, Aubron C
    Transfusion Strategy in Myocardial Infarction and Anemia.
    N Engl J Med. 2024;390:960.
    >> Share

  169. MARFELLA R, Prattichizzo F, Sardu C, Fulgenzi G, et al
    Microplastics and Nanoplastics in Atheromas and Cardiovascular Events.
    N Engl J Med. 2024;390:900-910.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016